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Alternative splicing and posttranslational modifications (PTMs) are major sources of protein diversity in
eukaryotic proteomes. The SR protein SF2/ASF is an oncoprotein that functions in pre-mRNA splicing, with
additional roles in other posttranscriptional and translational events. Functional studies of SR protein PTMs
have focused exclusively on the reversible phosphorylation of Ser residues in the C-terminal RS domain. We
confirmed that human SF2/ASF is methylated at residues R93, R97, and R109, which were identified in a global
proteomic analysis of Arg methylation, and further investigated whether these methylated residues regulate the
properties of SF2/ASF. We show that the three arginines additively control the subcellular localization of
SF2/ASF and that both the positive charge and the methylation state are important. Mutations that block
methylation and remove the positive charge result in the cytoplasmic accumulation of SF2/ASF. The conse-
quent decrease in nuclear SF2/ASF levels prevents it from modulating the alternative splicing of target genes,
results in higher translation stimulation, and abrogates the enhancement of nonsense-mediated mRNA decay.
This study addresses the mechanisms by which Arg methylation and the associated positive charge regulate the
activities of SF2/ASF and emphasizes the significance of localization control for an oncoprotein with multiple
functions in different cellular compartments.
Pre-mRNA splicing is a required step for the expression of
most human genes. Alternative splicing plays a key role in
regulating gene expression and is a major source of protein
isoform diversity. SR proteins are a family of closely related
and highly expressed eukaryotic RNA-binding proteins that
regulate both general and alternative splicing (22) and have
additional roles in other aspects of gene expression (41). SF2/
ASF, a prototypical member of the SR protein family, has a
modular structure with two RNA recognition motifs (RRMs),
which recognize a 7-nucleotide exonic splicing enhancer (ESE)
motif on pre-mRNA, and an RS domain with numerous re-
peats of serine-arginine dipeptides (Fig. 1A). SF2/ASF is re-
quired for general splicing, though sometimes interchangeably
with other SR proteins (33), and also plays a role in the reg-
ulation of alternative splicing in a concentration-dependent
manner, in part through the recognition of ESEs (16). In ad-
dition to its role as a broad-specificity splicing regulator, SF2/
ASF strongly enhances nonsense-mediated mRNA decay
(NMD) upon overexpression (65), stimulates translation both
in vivo and in vitro in an enhancer-dependent manner (50), and
functions as an adaptor protein for mRNA export (26). Some
of these additional functions of SF2/ASF reflect its ability to
shuttle between the nucleus and the cytoplasm (13). Reflecting
its multifaceted role as a regulator in various cellular pro-
cesses, SF2/ASF is a potent oncoprotein whose overexpression
by as little as 2-fold is sufficient to transform immortal rodent
fibroblasts (30). Conversely, the knockdown of SF2/ASF in-
duces G2 cell cycle arrest and apoptosis (39).
One of the ways through which the various activities of
SF2/ASF could be regulated is by posttranslational modifica-
tions (PTMs). Like alternative splicing, PTMs are an integral
part of gene regulation and provide another way of creating
protein isoform diversity, with widespread functional conse-
quences. Studies of PTMs in SR proteins have focused mostly
on reversible phosphorylation at multiple Ser residues within
the C-terminal RS domain, as regulated by a combination of
phosphatases and kinases (46). More recently, three methyl-
ated Arg residues (R93, R97, and R109) in human SF2/ASF
were identified in a global analysis of protein methylation (48)
(Fig. 1A). Arginine methylation is widespread in eukaryotes. In
the budding yeast Saccharomyces cerevisiae, the protein Npl3p,
which resembles both hnRNPs and SR proteins in primary
sequence and domain structure (7), is involved in mRNA ex-
port (38, 54) and undergoes Arg methylation at RGG motifs in
its C-terminal RGG/RS domain, catalyzed by Hmt1p (53). A
lack of Arg methylation causes defects in the export of Npl3p
from the nucleus (52), and the hypermethylation of RGG
motifs blocks its nuclear import (63). In mammals, the meth-
ylation of RGG motifs in the C-terminal Gly-rich domain of
the splicing factor hnRNP A2 promotes its nuclear localization
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(47). The methylated Arg residues in SF2/ASF are part of
Arg/Gly-rich motifs, which are very similar to those in Npl3p
and hnRNP A2, although these motifs differ in their locations
in SF2/ASF. Indeed, it was shown previously that SF2/ASF and
its close paralog SRp30c are methylated by the human ho-
molog of Hmt1p, PRMT1 (11, 21). PRMT1 is a type I meth-
yltransferase that catalyzes the formation of monomethyl and
asymmetric dimethyl Arg on proteins (59, 60) preferentially at
RGG/GRG and related motifs (28, 31).
To investigate the functional relevance of the modified
Arg residues of SF2/ASF, we mutated these residues, singly
or in combination, to Ala or Lys. After an extensive analysis
of the various functions of SF2/ASF, we report that the
three methylated Arg residues in the inter-RRM linker re-
FIG. 1. Localization and shuttling activity of wild-type and mutant SF2/ASF. (A) Modular structure of SF2/ASF and mutants in the inter-RRM
linker region. The three Arg residues in boldface type are methylated, and we mutated each one to Ala or Lys. (B) Indirect immunofluorescence
of HeLa cells transfected with wild-type or mutant T7-tagged SF2/ASF cDNA, with or without fusion to a nuclear retention signal peptide from
SC35 (NRS1) (17). (C) Indirect immunofluorescence of HeLa cells cotransfected with GFP and wild-type or mutant T7-tagged SF2/ASF.
(D) Indirect immunofluorescence of HeLa cells transfected with T7-tagged SF2/ASF or the A1A2A3 mutant with or without prior treatment with
10 ng/ml leptomycin B for 12 h. (E) Heterokaryon assay (13, 49). We transfected HeLa cells with T7-tagged SF2/ASF, K1K2K3, or SC35 as a
control. After 24 h, we treated the cells with cycloheximide, fused them with mouse NIH 3T3 cells using polyethylene glycol, and incubated them
for 2 h. After fixation, we determined the localization of the transiently expressed proteins in the heterokaryons by indirect immunofluorescence.
The panels in the right column show the merged images of T7 and DAPI signals. The arrows indicate mouse nuclei within human-mouse
heterokaryons, distinguished from human nuclei by their characteristic DAPI staining (middle column). The panels in the left column show
phase-contrast images of the same heterokaryons.
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gion control SF2/ASF’s subcellular localization, which in
turn determines the protein’s activity in enhancing NMD
and regulating the alternative splicing of endogenous pre-
mRNA targets.
MATERIALS AND METHODS
Plasmids. Plasmid pSP64-H6 (34) and the duplicated 5-splice-site (5ss)
version pSP64-5ssD-wt (65) were described previously. Plasmid pUC128SV
has a full-length -globin gene driven by its own promoter and the simian virus
40 (SV40) enhancer (14). The mutant version pUC128SV-T39 and the wild-
type and mutant duplicated 5ss versions, pUC-5ssD-wt and pUC-5SSD-mt,
respectively, were described previously (65). Mammalian expression plasmid
pCGT-SF2/ASF encodes a T7-tagged version of human SF2/ASF (12). We used
site-directed mutagenesis to create the various T7-tagged pCGT versions of
single-, double-, or triple-missense mutants in which the Arg residues at positions
93, 97, and 109 were changed to either Ala or Lys (see Table S1 in the supple-
mental material). Using pCGT-A1A2A3 and pCGT-K1K2K3 as templates, we
made pCGT-SM and pCGT-KM by site-directed mutagenesis, changing the Gly
residues in the RGG/GRG/RGR motifs to Ala. We replaced a ClaI-BstBI
fragment in plasmid pCGT-SF2/ASF-NRS1 (17) with the corresponding frag-
ments from pCGT-A1A2A3 and pCGT-K1K2K3 to create pCGT-A1A2A3-NRS1
and pCGT-K1K2K3-NRS1, respectively. We replaced the SacII-BamHI fragment
in pET9c-SF2/ASF(R/S) (35) with the corresponding fragment from pCGT-
A1A2A3 and pCGT-K1K2K3 to create pET9c-A1A2A3 and pET9c-K1K2K3, re-
spectively, for bacterial expression and purification. We added a C-terminal
6His tag to the cDNAs of wild-type SF2/ASF (wt-SF2/ASF), A1A2A3, and
K1K2K3 by PCR using their pCGT versions as templates. We then individually
subcloned these amplicons as XbaI-BamHI fragments into the mammalian ex-
pression vector pTT3 (20). Similarly, we inserted the amplified cDNAs of
A1A2A3 and K1K2K3 with an N-terminal T7 tag as BamHI-EcoRI fragments into
the retroviral vectors pBABE-puro and pWZL-hygro. Both pBABE-T7SF2/ASF
and pWZL-T7SF2/ASF were described previously (30). Plasmids pLCS-EDA
and pLCS-EDAmt, used for translation assays involving transient transfection, as
well as constructs used for in vitro translation, pLuc-3EDA and pLuc-
3EDAmt, were generous gifts from Javier Ca´ceres and were described previ-
ously (50).
Expression and purification of recombinant proteins. We purified recombi-
nant untagged SF2/ASF as described previously (35). Briefly, we expressed wild-
type or mutant SF2/ASF cDNAs in Escherichia coli cells by using pET9c-SF2/
ASF(R/S)-type plasmids, followed by a series of purification steps, including
cesium-chloride gradient centrifugation to remove nucleic acids, selective pre-
cipitation in low salt, urea denaturation, ion-exchange chromatography, and the
subsequent refolding of the protein. We purified C-terminal 6His-tagged SF2/
ASF expressed in human 293-EBNA1 (293E) cells grown in suspension using a
variation of a method reported previously (20). We transfected 293E cells with
wild-type or mutant pTT3-SF2/ASF-His and harvested the cells 3 to 4 days after
transfection. We resuspended the cells in lysis buffer (50 mM Tris-HCl [pH 8.0],
1 M NaCl, 10 mM imidazole, 20 mM -mercaptoethanol, 0.1% [vol/vol] Triton
X-100) and centrifuged them after sonication to remove insoluble material. We
then precipitated most of the cellular proteins by using ammonium sulfate at
40% saturation at 4°C and removed them by centrifugation. We then purified
the His-tagged proteins from the supernatant by nickel-agarose affinity chro-
matography.
Cell culture and transient and stable expression of proteins. We grew HeLa
and IMR90 cells in Dulbecco’s modified Eagle’s medium (Invitrogen) supple-
mented with 10% fetal bovine serum (Invitrogen) at 37°C with 5% CO2. We grew
293E suspension cultures in Joklik’s modified Eagle’s medium (JMEM) (Invitro-
gen) supplemented with 5% calf serum (Invitrogen). We transfected HeLa cells
with Fugene 6 reagent (Roche Diagnostics) according to the manufacturer’s
recommendations, unless otherwise stated. We transfected 293E cells using lin-
ear polyethylenimine (PEI 25000; Polysciences Inc.). We prepared a transfection
mix consisting of 1 g plasmid DNA, 2 g PEI, and 50 l of JMEM for every 1
ml of cell culture to be transfected. We then incubated the mix at room tem-
perature for 10 to 15 min and added it to the suspension culture, which we
maintained at a density of 2  105 cells/ml. For stable expression, we generated
retroviruses by cotransfecting pBABE or pWZL constructs of wild-type or mu-
tant SF2/ASF, along with a vesicular stomatitis G protein (VSV-G) expression
construct, into Phoenix cells (a gift from Scott Lowe), an ecotropic packaging cell
line expressing essential viral proteins (23). We used the resulting viruses to
infect primary human lung fibroblasts (IMR90) to establish stable cell lines
overexpressing wild-type or mutant SF2/ASF, as described previously (30).
Indirect immunofluorescence (IF). We determined the subcellular localiza-
tions of transiently expressed wild-type or mutant versions of SF2/ASF by indi-
rect immunofluorescence using the N-terminal T7 epitope tag, as described
previously (17). Briefly, we transfected HeLa cells grown on coverslips in six-well
plates with 1 g of wild-type or mutant pCGT-SF2/ASF. We fixed the cells with
4% (vol/vol) paraformaldehyde in phosphate-buffered saline (PBS) 36 h after
transfection for 30 min, followed by incubation for 5 min in 0.2% (vol/vol) Triton
X-100 to permeabilize the cells. We then incubated the cells with anti-T7 mono-
clonal antibody (MAb) (1:1,000; Novagen) for 1 h, washed the cells with PBS,
and incubated them with Alexa Fluor 488-conjugated goat anti-mouse IgG an-
tibody (1:1,000; Invitrogen) for 1 h. We mounted the coverslips onto slides using
ProLong Gold Antifade reagent with DAPI (4,6-diamidino-2-phenylindole) (In-
vitrogen) and imaged the cells with a fluorescent microscope (Axioskop 2 Plus;
Carl Zeiss) equipped with a camera (AxioCam; Carl Zeiss).
Shuttling assays. We transfected HeLa cells grown on coverslips with T7-
tagged wild-type or A1A2A3 mutant SF2/ASF, as described above. Twenty-four
hours after transfection, we incubated the cells in tissue culture medium supple-
mented with 10 ng/ml leptomycin B (Calbiochem) for an additional 12 h. We
then fixed and permeabilized the cells and analyzed them by IF, as described
above.
The heterokaryon assay to assess the shuttling activity of nuclear proteins was
described previously (13, 49). In short, to achieve a high transfection efficiency,
we electroporated 1  106 HeLa cells with 4 g of either pCGT7-SF2/ASF or
pCGT-K1K2K3 and plated the cells onto coverslips; we included pCGT-SC35 as
a negative control. We then coincubated the cells with an excess of untransfected
mouse NIH 3T3 cells for 3 h in medium supplemented with 50 g/ml cyclohex-
imide; we then increased the concentration of cycloheximide to 100 g/ml, with
additional incubation for 30 min. We fused the cells using polyethylene glycol
(PEG) and further incubated the resulting heterokaryons for 2 h in medium
containing 100 g/ml cycloheximide. We visualized the cells by IF using T7
antibody, as described above. We distinguished mouse nuclei (NIH 3T3) from
human nuclei (HeLa) in the heterokaryons by the former’s characteristic punc-
tate DAPI staining pattern.
Dual-luciferase assay and cellular fractionation. We transfected 40 to 50%
confluent HeLa cells grown in six-well plates with 0.4 g pLCS reporter (50), 0.2
g TK-Renilla luciferase (Promega), and 1.0 g of wild-type or mutant pCGT-
SF2/ASF. We lysed the cells by using passive lysis buffer (Promega) at 48 h
posttransfection and assayed the levels of firefly and Renilla luciferase using a
dual-luciferase assay kit (Promega), measuring the luminescence with a Mono-
light 2010 apparatus (Analytical Luminescence Lab). For cellular fractionation,
we harvested the cells 48 h after transfection by trypsinization, resuspended them
in PBS, and used 1/10 of the cell suspension for the luciferase assay. We collected
the remaining cells by centrifugation, resuspended them in a hypotonic buffer (10
mM HEPES [pH 8.0], 10 mM KCl, 1 mM MgCl2, 1 mM dithiothreitol, 0.5%
[vol/vol] Nonidet P-40), incubated them on ice for 5 min, and lysed them by
gentle pipetting. We centrifuged the lysate with intact nuclei and collected the
supernatant as the cytosolic fraction. We washed the nuclear pellet with PBS and
extracted the nuclear proteins by resuspending the pellet in Laemmli buffer. We
analyzed both nuclear and cytoplasmic fractions by Western blotting.
In vitro translation. In vitro translation reaction mixtures consisted of 200 ng
of in vitro-transcribed pLuc reporter mRNA, 200 ng of recombinant wild-type or
mutant SF2/ASF, and translation-competent HeLa cell extracts (6), incubated
for 30 min at 37°C, as described previously (50). We stopped the reactions by
dilution with 100 l of passive lysis buffer (Promega) and measured luminescence
as described above by using luciferase-activating reagent (Promega).
In vitro splicing. We prepared radiolabeled pre-mRNAs by the in vitro tran-
scription of plasmids pSP64-H6 and pSP64-5ssD-wt linearized with BamHI,
with SP6 RNA polymerase, in the presence of [-32P]UTP. We incubated the
pre-mRNAs under splicing conditions in HeLa nuclear or cytoplasmic S100
extracts, as described previously (43, 44). We extracted the RNAs and analyzed
them by denaturing PAGE and phosphorimager analysis on a Fujifilm FLA-5100
instrument (Fuji Medical Systems USA, Inc.). We quantified the band intensities
using Multi Gauge software, version 2.3 (Fujifilm).
RPA. We cotransfected 40 to 50% confluent HeLa cells grown in 10-cm plates
with 0.2 g green fluorescent protein (GFP) plasmid, 0.5 g wild-type or mutant
pCGT-SF2/ASF plasmid, and 2.5 g wild-type -globin or mutant (T-39) NMD
reporter plasmids. To test both NMD and 5ss selection, we cotransfected 0.2 g
GFP plasmid, 0.7 g SF2/ASF plasmid, and 2.1 g 5ssD-wt or 5ssD-mt plasmid.
We isolated total RNA 36 h after transfection by ultracentrifugation of the cell
lysates layered on a 5.7 M CsCl cushion at 20°C and carried out an RNase
protection assay (RPA) as described previously (25, 65). We analyzed the radio-
active protected fragments by denaturing PAGE and phosphorimaging, as de-
scribed above.
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Reverse transcription (RT)-PCR. We extracted total RNA from IMR90 cells
stably expressing wild-type or mutant SF2/ASF using Trizol reagent (Invitrogen)
and reverse transcribed 2 g from each RNA sample using Superscript-II (In-
vitrogen). We amplified the cDNAs corresponding to transcripts of endogenous
target genes of SF2/ASF by PCR using Taq Gold polymerase (Invitrogen) with
specific primers and conditions described previously (30).
Antibodies and Western blotting. We lysed cells in Laemmli sample buffer and
analyzed the proteins by Western blotting with various primary antibodies spe-
cific for SF2/ASF (MAb AK96), SRp55 (MAb 9-1-56), Myc (MAb 9E10), T7
(Novagen), -catenin (Transduction Labs), and caspase-3 (a gift from Yuri
Lazebnik). The secondary antibody was goat anti-mouse IgG conjugated to
Alexa Fluor 532 (Invitrogen). After washing, we scanned the nitrocellulose
membranes (Whatman) on a Fujifilm FLA-5100 instrument equipped with a
532-nm laser and quantified fluorescence band intensities as described above.
MS. Wild-type or mutant versions of SF2/ASF were purified from 293E cells
as described above and analyzed by mass spectrometry (MS). Briefly, we sepa-
rated the purified proteins by SDS-PAGE and stained them with GelCode blue
(Pierce). We digested and processed the bands for analysis as described previ-
ously (2). We analyzed the tryptic peptides either by liquid chromatography
(LC)-tandem MS (MS/MS) on a linear trap quadrupole mass spectrometer
(Thermo) or by targeted fragmentation on a matrix-assisted laser desorption
ionization–time of flight (MALDI-TOF) spectrometer (Applied Biosystems) (8).
We analyzed the LC-MS/MS runs using the X!Tandem search engine (19) with
the following parameters: variable modifications included mono-, di-, and trim-
ethylation of Lys and mono- or dimethylation of Arg residues. For targeted
fragmentation, we first analyzed the precursor mass list using either the Profound
or Peptidemap software package (http://prowl.rockefeller.edu/). We then se-
lected peaks with precursor masses consistent with methylated peptides for
fragmentation and analyzed the resulting spectra using MS-Product (http:
//prospector.ucsf.edu/). We resolved ambiguities by comparisons with theoretical
spectra derived from all possible methylation patterns.
RESULTS
SF2/ASF is methylated at Arg residues 93, 97, and 109. We
expressed C-terminal 6His-tagged SF2/ASF in human 293-
EBNA1 (293E) cells, purified it, and analyzed it by MS. We
verified the results by MS/MS analysis, which confirmed that
SF2/ASF is methylated at Arg residues 93, 97, and 109 (data
not shown), consistent with previous observations from global
proteomic studies (48).
The methylated arginines affect the nucleocytoplasmic dis-
tribution of SF2/ASF. Based on studies of Npl3p in yeast and
of other RNA-binding proteins, we hypothesized that the sites
of Arg methylation in SF2/ASF (Fig. 1A) might influence its
localization. We anticipated that changes in the distribution of
SF2/ASF between the nucleus and cytoplasm may affect the
alternative splicing of target genes as well as its other func-
tions. To investigate the functional significance of the modifi-
cations, we mutated these sites singly or in combination to Ala
to prevent methylation as well as abolish the positive charge.
Similarly, as a control, we also mutated these residues to Lys to
retain the positive charge but presumably prevent methylation.
We determined the subcellular localization of wild-type SF2/
ASF (wt-SF2/ASF) and the missense mutants by indirect im-
munofluorescence (IF) via an N-terminal T7 epitope tag after
the transient transfection of the cDNAs into HeLa cells. We
observed that the triple-Ala mutant A1A2A3 was predomi-
nantly cytoplasmic, in contrast to the corresponding triple-Lys
substitution mutant K1K2K3 or wt-SF2/ASF, which localized to
nuclear speckles (Fig. 1B). The single- or double-Ala mutants
displayed intermediate phenotypes (Fig. 1C).
To test whether the A1A2A3 mutant could still shuttle, we
treated transiently transfected HeLa cells with a nuclear export
inhibitor, leptomycin B. The accumulation of T7 signal in the
nucleus upon treatment with the inhibitor indicates that
A1A2A3 shuttles between the nuclear and cytoplasmic com-
partments (Fig. 1D). We also tested the shuttling of the nu-
clear protein K1K2K3 by using a heterokaryon assay and found
it to be the same as that of wt-SF2/ASF (Fig. 1E). The hetero-
karyon assay (49), which is used to test the shuttling activity of
nuclear proteins, could not be used in the case of the A1A2A3
mutant, as it showed predominant cytoplasmic localization.
Reduced activity of the A1A2A3 mutant in general and alter-
native splicing in vitro. To analyze the effect of mutations in
the inter-RRM linker on the splicing activity of these proteins,
we purified untagged recombinant SF2/ASF and the A1A2A3
and K1K2K3 versions to homogeneity from E. coli cells. We
also purified posttranslationally modified versions of these pro-
teins after expression in 293E cells with a C-terminal 6His
tag (Fig. 2A). We then tested the purified proteins for their
ability to complement HeLa S100 extracts to carry out the
general splicing of various pre-mRNAs. We observed that the
K1K2K3 mutant was as active as wt-SF2/ASF, but the A1A2A3
mutant was approximately 4-fold less active with -globin pre-
mRNA (Fig. 2B and D and see Fig. S1 in the supplemental
material). We obtained similar results with other substrates,
including Ftz, AdML, IgM-M1M2, IgM-C1C2, and -crystallin
(data not shown).
To test alternative splicing activity in vitro, we used a model
-globin pre-mRNA with a duplicated 5ss in intron 1 (65).
Again, we observed that the K1K2K3 mutant was as efficient as
wt-SF2/ASF in promoting proximal 5ss use in HeLa nuclear
extracts, whereas the A1A2A3 mutant was slightly less active
(Fig. 2C and E). In all the assays, the trend was similar and did
not vary when the proteins were obtained from bacteria or
mammalian cells. However, the specific activity of SF2/ASF
obtained from 293E cells was consistently higher than that
from bacteria (data not shown), which may reflect differences
in PTMs and/or in purification/renaturation protocols and sol-
ubility. The A1A2A3 protein, irrespective of its source, was
slightly less soluble under splicing conditions, especially at
higher concentrations, which may be one of the reasons why
the triple-Ala mutant was less active in these cell-free assays.
The A1A2A3 mutant fails to modulate splicing of endogenous
pre-mRNAs. We recently identified BIN1 and MNK2 pre-
mRNAs as endogenous targets of SF2/ASF (30). To test the
effect of the mutant proteins on the alternative splicing of these
transcripts, we stably expressed cDNAs encoding T7-tagged,
wt-SF2/ASF or the mutant A1A2A3 and K1K2K3 versions in
primary human lung fibroblasts (IMR90) using retroviral
transduction. We analyzed total RNA extracted from transduc-
tant pools by RT-PCR to detect the isoforms of the above-
described target genes. We observed that the overexpression of
both wt-SF2/ASF and the K1K2K3 mutant promoted the inclu-
sion of exon 12a in BIN1 and led to an increase in the levels of
the MNK2 alternatively spliced isoform MNK2b; however, the
K1K2K3 mutant was less active due to its lower level of expres-
sion. In contrast, the relative levels of alternatively spliced
isoforms of the target genes upon the overexpression of the
A1A2A3 mutant were similar to those of the empty vector
control (Fig. 3).
The triple-Ala mutant A1A2A3 fails to enhance NMD. Splic-
ing is a nuclear process (9), and a nuclear activity of SF2/ASF
appears to be required for its stimulatory effect on NMD (65).
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Therefore, we next assayed the activities of the above-de-
scribed SF2/ASF mutants to enhance NMD by using an RNase
protection assay (RPA). We used a full-length -globin gene
and a mutant version with a nonsense mutation in codon 39 in
exon 2 as reporters. The nonsense mutation introduces a pre-
mature termination codon (PTC), making the mRNA suscep-
tible to NMD (Fig. 4A, left) (56, 64). RPA showed that upon
overexpression, wt-SF2/ASF as well as the K1K2K3 version
strongly enhanced NMD of the T39 (mut) mRNA, whereas the
mislocalized A1A2A3 mutant was similar to the empty vector
control (Fig. 4B and E). The single- and double-Ala mutants
had intermediate effects (Fig. 4C and E).
To assay both alternative splicing and NMD using RPA, we
used a derivative of -globin with a 5-splice-site (5ss) dupli-
cation in the first exon (5ssD-wt) (65). Because of alternate
5ss usage, the pre-mRNA gives rise to two distinct mRNAs: a
longer proximal mRNA and a shorter distal mRNA. The mu-
tant version of this gene (5ssD-mt) carries a point mutation
that introduces a PTC into the proximal, but not the distal,
spliced mRNA (Fig. 4A, right). As reported previously (65),
SF2/ASF promoted the selection of the proximal 5ss and
enhanced NMD of the resulting mRNA. In contrast, the
A1A2A3 mutant efficiently promoted proximal splice-site selec-
tion but failed to enhance NMD; the K1K2K3 mutant, however,
showed activity identical to that of wt-SF2/ASF (Fig. 4D, F,
and G). Again, as described above, the single- and double-Ala
mutants had intermediate effects (data not shown).
In contrast to the transduced IMR90 cells, which result in
only about a 2-fold overexpression of SF2/ASF and the various
mutants (Fig. 3A), these experiments involving transient co-
transfection result in substantial overexpression in the cells
that take up the DNA. Because the A1A2A3 mutant retains
some ability to shuttle, the high levels of overexpression pre-
sumably allow enough of the A1A2A3 protein to transit
through the nucleus to alter the splicing of -globin pre-
mRNA with a 5ss duplication (Fig. 1D and 4D). In contrast,
with more physiological levels of overexpression, the triple-Ala
mutant fails to modulate the splicing of target genes (Fig. 3).
Furthermore, the solubility and/or folding of the transiently
overexpressed proteins is not likely to be affected in HeLa
cells, which could explain the observed parity between the
activities of A1A2A3 and wt-SF2/ASF in promoting the selec-
FIG. 2. In vitro splicing activity of wild-type and mutant SF2/ASF. (A) Coomassie stain of an SDS-polyacrylamide gel showing the different
versions of recombinant SF2/ASF purified from either 293E cells or E. coli cells. (B) S100 complementation assay to test the general splicing
activity of wild-type or mutant SF2/ASF purified from 293E cells using a radiolabeled -globin minigene pre-mRNA. We added increasing amounts
of each protein (4, 8, 16, and 24 pmol) to otherwise identical reaction mixtures. The mobilities of pre-mRNA and mRNA are indicated on the right.
M, molecular weight marker; NE, splicing in nuclear extract. (C) In vitro splicing assay to test the alternative splicing activity of wild-type or mutant
SF2/ASF purified from 293E cells using a model -globin pre-mRNA with a duplicated 5ss derivative (65). The positions of the pre-mRNA and
the two spliced mRNA isoforms are indicated on the right. We supplemented the splicing reaction mixtures of HeLa nuclear extracts with
increasing amounts of each protein (4, 8, 16, and 24 pmol). (D) Graph showing quantification of phosphorimager signals from multiple experiments
described above (B). We normalized the mRNA intensities to the corresponding pre-mRNA intensities in each lane and plotted them as a
percentage of splicing as a function of the amount of protein added (n  2 to 3). Error bars indicate standard deviations (SD). (E) Graph showing
quantification of phosphorimager signals from multiple experiments described above (C). We divided the proximal-mRNA intensities by the sum
of proximal- and distal-mRNA intensities in each lane and plotted them as a percentage of proximal mRNA as a function of the amount of protein
added (n  2). Error bars indicate SD.
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tion of the proximal 5ss after cotransfection (Fig. 4D and F),
in contrast to the cell-free assays (Fig. 2C and E).
A nuclear-retained version of the A1A2A3 protein promotes
NMD. Based on the above-described observations, it seemed
plausible that the mislocalization of the A1A2A3 mutant was
responsible for its loss of function in NMD. To test this hy-
pothesis, we fused a nuclear retention signal (NRS) from the
nonshuttling SR protein SC35 to the A1A2A3 and K1K2K3
versions of SF2/ASF at their respective C termini. A C-termi-
nal fusion of the NRS sequence, in the case of wt-SF2/ASF,
results in a loss of shuttling activity (17). Furthermore, this
nuclear-retained version of SF2/ASF is active in splicing and
NMD (65), as well as in autoregulation (55), but fails to en-
hance translation in cells (50). Immunofluorescence analysis
confirmed that the fusion of the NRS sequence to the A1A2A3
mutant restored nuclear localization (Fig. 1B). Furthermore,
when assayed for NMD, the NRS version of the A1A2A3 mu-
tant was as efficient as wt-SF2/ASF in enhancing NMD, clearly
indicating that nuclear localization is essential for this activity
(Fig. 5).
The A1A2A3 protein is more active than wt-SF2/ASF in en-
hancing translation in cells. To test whether the triple-Ala
mutant of SF2/ASF can enhance translation, we used previ-
ously described reporter constructs in which either a wild-type
or a mutant ESE recognized by SF2/ASF is fused at the 5 end
of firefly luciferase (50). The cotransfection of the reporters
along with wild-type or mutant versions of SF2/ASF and sub-
sequent analysis of luciferase activity revealed that the A1A2A3
protein is twice as active as wt-SF2/ASF in promoting transla-
tion in an enhancer-dependent manner (Fig. 6A). The increase
in luciferase activity in the cytoplasm upon the overexpression
of A1A2A3 could be due to the following three reasons: in-
creased translation-stimulatory activity due to mutation,
greater accumulation of A1A2A3 in the cytoplasm, or increased
levels of luciferase mRNA in the cytoplasm due to enhanced
export. RT-PCR analysis of luciferase mRNA levels in nuclear
and cytoplasmic fractions from the transfected HeLa cells re-
vealed that A1A2A3 does not enhance mRNA export (Fig. 6B).
Furthermore, recombinant A1A2A3 was equally as active as
wt-SF2/ASF in enhancing the translation of the in vitro-tran-
scribed luciferase reporter in a cell-free assay with a transla-
tionally competent HeLa cell extract (Fig. 6C). We conclude
that the apparent increased activity of the A1A2A3 mutant in
enhancing translation in cells is due to its increased residence
time in the cytoplasm.
Tandem mass spectrometry reveals that the triple-Lys mu-
tant is dimethylated. Surprisingly, our results showed that in
all the assays, the K1K2K3 mutant had effects that were very
similar to those of wt-SF2/ASF. To address the possibility that
the substituted Lys residues at these positions undergo meth-
ylation, we expressed the K1K2K3 mutant in 293E cells and
analyzed the purified protein by mass spectrometry. MS/MS
analysis of one of the peptides corresponding to the region of
substitution revealed that the substituted Lys at position 109
was indeed dimethylated (Fig. 7). This unexpected finding
points toward the possibility that both the methylation state
and the positive charge at these positions could be responsible
for the localization of SF2/ASF (see Discussion).
To address the question of whether positive charge, meth-
ylation, or both are involved in controlling the localization of
SF2/ASF, we mutated the Gly residues surrounding the methyl-
arginine residues to Ala as well as Arg at position 111 to Lys,
FIG. 3. Effects of wild-type or mutant SF2/ASF on alternative splicing of endogenous transcripts in IMR90 cells. (A) We extracted total RNA
and protein from IMR90 cells stably overexpressing the indicated proteins after retroviral transduction (30). We analyzed total RNA by RT-PCR
and detected the expressed T7-tagged proteins and endogenous SRp55 and SF2/ASF by Western blotting. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase. (B and C) Graphs showing the levels of different mRNA isoforms of MNK2 (B) and BIN1 (C) after quantification of the
corresponding lanes in panel A.
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FIG. 4. Effect of overexpression of wild-type or mutant SF2/ASF on NMD. (A) Schematic representation of the wild-type (WT) and mutant
(MT) -globin reporters (left), the wild-type and mutant -globin reporters with a duplicated 5ss (right), and their corresponding RPA probes.
(B) We cotransfected a human -globin gene (wild type) or a mutant version with an in-frame PTC with wild-type or mutant versions of SF2/ASF
into HeLa cells. We extracted total RNA 36 h after transfection and analyzed it by RPA. We also cotransfected a GFP-expressing plasmid as an
internal reference and used -globin and GFP probes simultaneously for RPA. At the bottom, Western blotting with T7 antibody shows the
expression of each tagged protein. (C) Effect of single- or double-Ala mutants of SF2/ASF on sensitivity to a PTC upon overexpression. We
performed transient cotransfection and RPA as described above (B). (D) A cotransfected -globin minigene (wild type) has a duplicated 5ss and
can be spliced via either the proximal or the distal 5ss; the mutant version has an in-frame PTC such that the proximal mRNA is susceptible to
NMD (65). We analyzed total RNA recovered from HeLa cells by RPA after transient cotransfection with wild-type or mutant versions of
SF2/ASF. We cotransfected a GFP plasmid as a reference and used -globin and GFP probes simultaneously. The bottom panel shows the
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resulting in the SM mutant. As a control, we also made the
corresponding mutations (Gly to Ala and Arg111 to Lys) in the
K1K2K3 version, giving rise to the KM mutant (see Fig. S2A in
the supplemental material). All the Gly-to-Ala changes disrupt
the RGG/GRG motifs, whereas the Arg111-to-Lys substitution
disrupts an RGR motif (59).
We hypothesized that if methylation is responsible for the
mislocalization of SF2/ASF, and methylation at these positions
is dependent upon RGG motifs, then replacing the glycines
should result in a phenotype similar to that observed for the
A1A2A3 mutant. Furthermore, if methylation of the substi-
tuted Lys in K1K2K3 also depends upon the introduced KGG
and related motifs, which seems highly unlikely, the KM mu-
tant should also behave like the triple-Ala mutant. Alterna-
tively, if positive charge alone, and not methylation, is involved
in the regulation of SF2/ASF localization, then both SM and
KM mutants should behave like wt-SF2/ASF.
Both the SM and KM versions of SF2/ASF showed predom-
inant nuclear localization, with only slight cytoplasmic staining
(see Fig. S2B in the supplemental material). Both proteins
showed NMD enhancement activities similar to that of wt-SF2/
ASF (Fig. S2C). Although these results suggest that positive
charge, and not methylation, controls SF2/ASF localization,
they are based on the assumption that the RGG-type motifs
are essential for the methylation of the Arg residues, which
may not be the case, as methylation by PRMT1 is not restricted
strictly to RGG and related motifs, and/or other methyltrans-
ferases may also modify SF2/ASF (see Discussion). Although
the possibility still remains that both the Arg residues in SM
and the Lys residues in KM undergo methylation, these results
reaffirm the importance of positive charge in controlling the
localization of SF2/ASF (see Discussion).
DISCUSSION
The coordinated and sequential events that lead to regulated
gene expression in eukaryotes are extremely complex, span-
ning across cellular compartments and requiring numerous
protein and RNA factors at various stages and at specific
locations. When a single protein factor, such as SF2/ASF, is
involved in multiple posttranscriptional events, it is essential
that its movements between cellular compartments be tightly
regulated. SF2/ASF is a shuttling protein that shows predom-
inant nuclear localization in the steady state (13). Within the
nucleus, SF2/ASF accumulates in nuclear speckles, and its
recruitment to active sites of transcription is modulated by the
phosphorylation of Ser residues in the RS domain and various
protein-protein interactions (46). The phosphorylation of SF2/
ASF also modulates its subcellular localization (32). The RS
domain is required for the shuttling of SF2/ASF (13) and
contributes to its nuclear localization (12).
Here we have demonstrated that additional signals that con-
trol the cellular localization of SF2/ASF are present in the
linker between RRM1 and RRM2. The Arg residues in this
expression of each tagged protein analyzed by Western blotting. (E) Quantification of phosphorimager signals from multiple experiments described
above (B and C). We normalized the individual mRNA intensities to the corresponding GFP intensities in each lane. We plotted the ratios of
normalized mutant mRNA to wild-type mRNA intensities to show the relative NMD enhancement upon the overexpression of each protein. (F)
Quantification of phosphorimager signals from multiple experiments described above (D). The plot shows individual wild-type proximal- and
wild-type distal-mRNA intensities normalized to the corresponding GFP intensities in each lane. (G) Same as panel F. We plotted the normalized
intensities of both wild-type and mutant proximal-mRNA levels to show the NMD enhancement upon the overexpression of the depicted proteins
(n  2 to 5, and error bars show SD [E to G]).
FIG. 5. Enhancement of NMD by SF2/ASF or mutants fused to a
nuclear retention signal. We cotransfected T7-tagged, wt-SF2/ASF or
the A1A2A3 and K1K2K3 mutants, with or without the NRS1 peptide
from SC35 fused at the C terminus, with -globin with or without a
PTC. (A) RPA of total RNA after transient expression, as described in
the legend of Fig. 4A. At the bottom are Western blots with anti-T7
antibody to detect the expressed tagged proteins and endogenous
-catenin as a reference. (B) Quantification of phosphorimager signals
from multiple experiments described above (A). We normalized the
individual mRNA intensities to GFP mRNA and plotted the ratios of
normalized mutant to wild-type mRNA intensities as described in the
legend of Fig. 4C (n  2 to 5; error bars indicate SD).
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linker region, in particular R93, R97, and R109, are methyl-
ated (48) and are important for correct localization, as we
found that mutating these residues simultaneously to Ala re-
sulted in cytoplasmic rather than nuclear accumulation.
The role of the SF2/ASF inter-RRM linker in RNA binding
is unclear, as a structure of full-length SF2/ASF or its two
RRMs in complex with RNA is lacking. Evidence from the
structures of other two-RRM proteins, such as UP1, Sex-
lethal, and nucleolin, indicates that the inter-RRM linkers,
which are disordered when unbound, cooperate with the
RRMs in binding the nucleic acid by providing increased af-
finity and specificity (42). In our study, the triple-Lys mutant
was functionally indistinguishable from wt-SF2/ASF, and the
triple-Ala mutant was as active as wt-SF2/ASF in promoting
translation in vitro, suggesting that RNA binding was not af-
fected by these substitutions.
The three guanidino nitrogen atoms in the Arg side chain
can potentially form five hydrogen bonds (H bonds) with H-
bond acceptors in RNA, resulting in a network of H-bond
interactions, which are not possible with Lys, as it has a single
terminal amino group (10, 15). For example, a short Arg-rich
basic peptide from the HIV-1 Tat protein binds specifically to
the transactivation-responsive region RNA, and a Lys substi-
tution results in a loss of binding and transactivation (15).
The methylation of the two terminal amino groups in the
Arg side chain does not alter the positive charge but increases
the hydrophobicity, makes the side chain bulkier, and, most
importantly, blocks any potential H-bond formation. This
could provide a potential means of regulating protein-RNA as
well as protein-protein interactions involving SF2/ASF such
that the methylation of the Arg residues abolishes some inter-
actions based on H bonding while leaving electrostatic inter-
actions unaffected. For example, Pro-rich motifs in Sam68 in-
teract with both SH3 and WW domains present in interacting
partners; the methylation of RG repeats that flank the Pro-rich
motifs reduces the binding of Sam68 to the SH3 domains of
p59fyn and phospholipase C-	1 without affecting binding to the
WW domain of FBP30 (4).
Because the motif recognized by PRMT1 is not limited
strictly to RGG and related sequences (60), it is possible that
other Arg residues of SF2/ASF are also modified. One prece-
dent is the methylation of R3 in histone H4 by PRMT1, in
which the methylated Arg is not part of an Arg/Gly-rich region
(58). As in the case of histones, the methylation state in the
SF2/ASF linker region may control various protein-protein
interactions, either directly or by influencing other modifica-
tions of SF2/ASF, such as the phosphorylation of the RS do-
main. Such regulation via Arg methylation, in conjunction with
phosphorylation-dephosphorylation cycles of the RS domain,
could play a role in the localization and trafficking of SF2/ASF
FIG. 6. Effect of wild-type or mutant SF2/ASF on ESE-dependent
stimulation of translation. (A) Diagram of the translation reporter with
an in-frame fibronectin extradomain A (EDA) wild-type or mutant
ESE upstream of the firefly luciferase open reading frame (ORF) (50)
(top). We cotransfected HeLa cells with the reporter, wild-type or
mutant T7-tagged SF2/ASF cDNA, and a Renilla luciferase reporter as
a control for transfection efficiency. We harvested the cells after 48 h
and analyzed them by a dual-luciferase reaction (DLR) assay. The
bottom shows the ratios of firefly activity to Renilla luciferase activity
(n  4; error bars indicate SD). (B) Subcellular distribution of the
luciferase reporter mRNAs upon the overexpression of wild-type or
mutant SF2/ASF. We prepared nuclear and cytosolic fractions from
aliquots of the transfected cells used for the DLR assay described
above (A) and measured the levels of firefly reporter mRNA by RT-
PCR as well as endogenous GAPDH mRNA as a reference (bottom
two panels). Western blots show the levels of the nuclear c-Myc pro-
tein and cytosolic caspase-3 protein to verify proper fractionation (top
two panels). (C) Effect of wild-type or mutant SF2/ASF on stimulation
of translation in vitro. At top is a diagram of the in vitro reporter (50).
We incubated in vitro-transcribed reporter mRNAs (200 ng) with three
copies of wild-type or mutant EDA ESE in a HeLa cell translation
extract with or without 200 ng of recombinant wild-type or mutant
SF2/ASF at 37°C for 30 min. The histogram shows the luciferase
activity for each reaction. RLU, relative light units.
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between cellular compartments. A precedent for this type of
cross talk was observed previously for Npl3p of budding yeast
(63). The phosphorylation of the RS domain is essential for the
interaction of SF2/ASF with transportin-SR2 (TRN-SR2),
which acts as a receptor for the nuclear import of SR proteins
(36). Furthermore, the phosphorylation state of SF2/ASF in-
fluences its activity as an adaptor protein for Tip-associated
protein (TAP)-mediated mRNA export (27, 37). However,
when we analyzed the interactions of wt-SF2/ASF and its mu-
tant versions (A1A2A3 and K1K2K3) with either TAP or TRN-
SR2, we observed that all versions of SF2/ASF interacted sim-
ilarly with these two proteins, arguing against the possibility
that these three Arg residues, or their methylation states, affect
these interactions (data not shown).
In addition to changing the properties of binding sites and
affecting other modifications, methylated arginines are also
involved directly in protein-protein interactions. The Tudor
domain of the SMN protein interacts directly with symmet-
ric dimethyl Arg residues in proteins with this modification
(18). However, proteins and their respective domains that
may bind to asymmetric dimethyl Arg residues in SF2/ASF,
and other proteins with the same modification, are yet to be
discovered.
The triple-Ala mutant of SF2/ASF was unable to enhance
NMD and failed to modulate the alternative splicing of endog-
enous target pre-mRNAs when modestly overexpressed. Fur-
thermore, due to the accumulation of the protein in the cyto-
plasm, A1A2A3 was more efficient at enhancing the translation
of a luciferase reporter than wt-SF2/ASF. When we restored
the nuclear localization of the A1A2A3 protein by the C-ter-
FIG. 7. Tandem mass spectrometry of the K1K2K3 protein. (A) Coomassie-stained SDS-polyacrylamide gel showing the different versions of
SF2/ASF purified from 293E cells before and after treatment with calf intestinal phosphatase (CIP). (B) We purified wild-type and mutant
SF2/ASF expressed in 293E cells, treated them with calf intestinal phosphatase, separated them by SDS-PAGE, and stained them with GelCode
blue. Next, we excised individual bands, digested them with trypsin, and analyzed them by MALDI-TOF MS. We selected peptides corresponding
to the region of interest and analyzed them by MS/MS. The MS/MS spectrum shown is from one such peptide from the K1K2K3 protein with two
methyl groups. The largest peak (b16  1,112.5) has a match only when one of the three Lys residues is dimethylated and not if two of them are
monomethylated. The peptides marked with asterisks correspond to peptide mass peaks that can occur only when Lys at position 109 is
dimethylated. The ion matches when one of the three Lys residues is dimethylated [K2(me)] are represented at the bottom, indicating that Lys109
is indeed dimethylated in this peptide.
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minal fusion of a nuclear retention sequence from the non-
shuttling SR protein SC35 (17), the resulting A1A2A3-NRS1
protein was as effective in promoting NMD as wt-SF2/ASF,
demonstrating that the effects observed with A1A2A3 were due
to mislocalization. However, we note that at high levels of
overexpression, A1A2A3 was as effective as SF2/ASF in pro-
moting the selection of the proximal 5ss of the -globin model
pre-mRNA with a duplicated 5ss, most likely due to its ability
to shuttle, resulting in enough protein in the nucleus to mod-
ulate alternative splicing. However, it is interesting that even at
high levels of overexpression and with the ability to shuttle,
A1A2A3 was inactive in promoting NMD. The ability of SF2/
ASF to regulate splicing in a concentration-dependent manner
is well documented (16), whereas the precise mechanisms un-
derlying the effect of SF2/ASF in NMD (65) remain largely
unknown, although it was shown recently that the transient
overexpression of SF2/ASF promotes an increase in the effi-
ciency of the pioneer round of translation (51). Nonetheless,
we have conclusively confirmed the initial observation (65) that
the nuclear localization of SF2/ASF is essential for its activity
in enhancing NMD.
Although the detailed mechanisms through which SF2/ASF
promotes transformation are understood only in part (30), an
improper cellular localization of SF2/ASF may be one of the
ways through which it exerts its oncogenic activity, especially
due to its regulatory roles in multiple posttranscriptional
events in both the nucleus and the cytoplasm. For example, in
sputum, an increase in the cytoplasmic levels of another splic-
ing factor, hnRNP A2, serves as a powerful predictor of lung
cancer almost a year prior to clinical detection (57), suggesting
that such a change may be a prerequisite for the transforma-
tion of lung epithelial cells.
Intriguingly, the K1K2K3 mutant was functionally indistin-
guishable from wt-SF2/ASF, pointing toward the importance
of charge at these positions as opposed to the methylation state
per se. Studies of the yeast SR-like protein Npl3p (52, 63);
other shuttling RNA-binding proteins in mammals, such as
some hnRNPs (24, 40, 47); and the transcription factors
TAF15 and Ewing’s sarcoma oncoprotein (EWS) (3, 29) have
shown that the Arg methylation of RGG motifs is involved in
controlling the nucleocytoplasmic distribution of these pro-
teins. However, no obvious defect in the nuclear export or
localization of Npl3p was observed upon the replacement of
Arg residues in the RGG motifs with Lys (45, 61). A similar
observation was made with the yeast protein Hrp1p, which
resembles hnRNPs and also contains RGG motifs; but in this
case, additional changes of the Arg residues to Glu or Gln
resulted in cytoplasmic localization, most likely through im-
paired nuclear import (61). In mammals, EWS interacts with
components of both the transcriptional machinery, via its N-
terminal transactivation domain, as well as the splicing machin-
ery, via its C-terminal domain, and is thought to couple tran-
scription and splicing (62). EWS is methylated at two RGG
boxes, RGG2 and RGG3, which are required for its nuclear
localization (3, 5). However, only the replacement of Arg res-
idues in the RGG boxes with Ala, and not Lys, altered the
transcriptional activity of EWS (1).
Our observation that at least one of the substituted lysines
(R109K) in the K1K2K3 version of SF2/ASF was dimethylated
suggests that both the methylation state and the positive
charge at these positions may contribute to the localization of
SF2/ASF. Although it is possible that naturally occurring Lys
residues in SF2/ASF are methylated, we had not expected to
find methylation of the substituted Lys residues. Also, in the
absence of quantitative mass spectrometry data, we do not
know what fraction of the total K1K2K3 protein expressed in
293E cells underwent this modification, so it is possible that
dimethylation of the substituted Lys109 is present in only a
small fraction of the protein.
Experiments involving the SM and the KM mutants (see Fig.
S2 in the supplemental material), which had activities similar
to those of wt-SF2/ASF, did not conclusively solve the conun-
drum of charge versus methylation due to the possibility that
even in the absence of the glycines in the RGG/GRG motifs,
the Arg residues in the SM mutant might still be methylated by
PRMT1 and/or other methyltransferases. Furthermore, the
treatment of HeLa cells with the specific PRMT1 inhibitor
AMI-1 did not alter the localization of either endogenous
SF2/ASF or transfected wt-SF2/ASF and K1K2K3 proteins,
consistent with the importance of positive charge (data not
shown). However, PRMT1 methylates many proteins in the
cell; therefore, blocking its activity may affect various cellular
processes, including nucleocytoplasmic trafficking, which could
account for the observed negative result. Another possibility is
that methylation of the three arginines in SF2/ASF may also
involve other methyltransferases, which may be active when
PRMT1 is inhibited.
In summary, our findings underscore the importance of the
proper localization of SF2/ASF for its activity in key nuclear
and cytoplasmic processes. We have further identified the sig-
nals that control the distribution of SF2/ASF between nucleus
and the cytoplasm and also generated mutants of SF2/ASF
with a partial loss of function. Such mutants will prove useful
in future studies to dissect the mechanisms through which
SF2/ASF affects various normal cellular processes as well as
oncogenic transformation.
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